Vital Signs The Analyst's Perspective - April 2016 Issue

USD 450

* Required Fields

USD 450


Be the first to review this product

This Vital Signs issues trends in orphan drugs, genetic research apps, Thermo Fisher Scientific's acquisition of Affymetrix, and the Zika Virus.

Table of Contents

Vital Signs The Analyst's Perspective - April 2016 IssueVital Signs - April 2016 IssueApril 2016 Issue




Related Research

Release Date : 02-Mar-17

Region : Global

Release Date : 29-Apr-2016

Region : Global

Release Date : 29-Oct-2013

Region : Global

Why Frost & Sullivan

Working with the CEO’s growth team to create a vision based on a transformation growth strategy

Creating content-based digital marketing strategies that leverage our research perspective to differentiate and “tell your story”

Tracking over 1000 emerging technologies and analyzing the impact by industry and application to reveal the companies to watch in each sector

The Frost & Sullivan team is based in our 45 global offices and have developed a powerful global understandings of how industries operate on a global level.